JP2008528671A5 - - Google Patents

Download PDF

Info

Publication number
JP2008528671A5
JP2008528671A5 JP2007553700A JP2007553700A JP2008528671A5 JP 2008528671 A5 JP2008528671 A5 JP 2008528671A5 JP 2007553700 A JP2007553700 A JP 2007553700A JP 2007553700 A JP2007553700 A JP 2007553700A JP 2008528671 A5 JP2008528671 A5 JP 2008528671A5
Authority
JP
Japan
Prior art keywords
treatment
use according
histone deacetylase
deacetylase inhibitor
treatment comprises
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007553700A
Other languages
English (en)
Other versions
JP5156392B2 (ja
JP2008528671A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2006/000391 external-priority patent/WO2006082428A2/en
Publication of JP2008528671A publication Critical patent/JP2008528671A/ja
Publication of JP2008528671A5 publication Critical patent/JP2008528671A5/ja
Application granted granted Critical
Publication of JP5156392B2 publication Critical patent/JP5156392B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Description

本発明の併用療法は、広範囲の癌の治療における使用に好適である。本明細書で使用される用語「癌」は、腫瘍、新生物、癌、肉腫、白血病、リンパ腫などを意味する。例えば、癌には、限定されるものでないが、白血病およびリンパ腫、例えば皮膚T細胞リンパ腫（CTCL）、非皮膚末梢T細胞リンパ腫、ヒトT細胞リンパ向性ウイルス（HTLV）に関連するリンパ腫、例えば、成人T細胞白血病／リンパ腫（ATLL）、急性リンパ性白血病、急性非リンパ指向性白血病、慢性リンパ性白血病、慢性骨髄性白血病、ホジキン病、非ホジキンリンパ腫、および多発性骨髄腫、小児期固形腫瘍、例えば脳腫瘍、神経芽細胞腫、網膜芽細胞腫、ウイルムス腫瘍、骨腫瘍、および軟組織肉腫、成人の通常の固形腫瘍、例えば頭部および頸部癌（例えば、口腔、喉頭、および食道の）、尿生殖器癌（例えば、前立腺、膀胱、腎、子宮、卵巣、精巣、直腸、および大腸）、肺癌、乳癌、膵臓癌、黒色腫およびその他の皮膚癌、胃癌、脳癌、肝臓癌および甲状腺癌が含まれる。

Claims (28)

  1. 癌の治療用の医薬品の製造におけるヒストンデアセチラーゼ阻害剤の使用であって、上記治療が(i)上記ヒストンデアセチラーゼ阻害剤および(ii)他の化学治療薬または上皮成長因子レセプター阻害剤を用いる治療を含んでなる上記使用。
  2. ヒストンデアセチラーゼ阻害剤が次式：
    Figure 2008528671
     ［式中、Aは無置換のフェニル基であり；
    Q1は共有結合またはC1〜7アルキレン基であり；
    Jは式：
    Figure 2008528671
     （式中、R1は水素、C1〜7アルキル、C3〜20ヘテロシクリル、C5〜20アリールである）
    であり；そして
    Q2は式：
    Figure 2008528671
     である］
    で表される化合物ならびにそれらの製薬上許容される塩および溶媒和物から選択される、請求項１に記載の使用。
  3. ヒストンデアセチラーゼ阻害剤が以下の化合物およびその製薬上許容される塩および溶媒和物から選択される、請求項１に記載の使用。
    Figure 2008528671
  4. ヒストンデアセチラーゼ阻害剤が以下の化合物である、請求項１に記載の使用。
    Figure 2008528671
  5. 上記治療が(i)上記ヒストンデアセチラーゼ阻害剤および(ii)他の化学治療薬を用いる治療を含んでなる、請求項１〜４のいずれか1項に記載の使用。
  6. 上記治療が(i)上記ヒストンデアセチラーゼ阻害剤および(ii)上皮成長因子レセプター阻害剤を用いる治療を含んでなる、請求項１〜４のいずれか１項に記載の使用。
  7. (i)上記ヒストンデアセチラーゼ阻害剤および(ii)シスプラチン、5-フルオロウラシル、オキサリプラチン、トポテカン、ゲムシタビン、ドセタキセル、ドキソルビシン、タモキシフェン、デキサメタゾン、5-アザシチジン、クロランブシル、フルダラビン、Tarceva(登録商標)、Alimta(登録商標)、メルファランから選択される化合物、ならびにそれらの製薬上許容される塩および溶媒和物を用いる治療を含んでなる、請求項１〜４のいずれか１項に記載の使用。
  8. 上記治療が(i)上記ヒストンデアセチラーゼ阻害剤と(ii)Tarceva(登録商標)を用いる治療を含んでなる、請求項１〜４のいずれか１項に記載の使用。
  9. 上記治療が(i)上記ヒストンデアセチラーゼ阻害剤と(ii)デキサメタゾンを用いる治療を含んでなる、請求項１〜４のいずれか１項に記載の使用。
  10. 上記治療が(i)上記ヒストンデアセチラーゼ阻害剤と(ii)5-フルオロウラシルを用いる治療を含んでなる、請求項１〜４のいずれか１項に記載の使用。
  11. 上記治療が(i)上記ヒストンデアセチラーゼ阻害剤と(ii)シスプラチンを用いる治療を含んでなる、請求項１〜４のいずれか１項に記載の使用。
  12. 上記治療が(i)上記ヒストンデアセチラーゼ阻害剤と(ii)オキサリプラチンを用いる治療を含んでなる、請求項１〜４のいずれか１項に記載の使用。
  13. 上記治療が(i)上記ヒストンデアセチラーゼ阻害剤と(ii)トポテカンを用いる治療を含んでなる、請求項１〜４のいずれか１項に記載の使用。
  14. 上記治療が(i)上記ヒストンデアセチラーゼ阻害剤と(ii)ゲムシタビンを用いる治療を含んでなる、請求項１〜４のいずれか１項に記載の使用。
  15. 上記治療が(i)上記ヒストンデアセチラーゼ阻害剤と(ii)ドセタキセルを用いる治療を含んでなる、請求項１〜４のいずれか１項に記載の使用。
  16. 上記治療が(i)上記ヒストンデアセチラーゼ阻害剤と(ii)ドキソルビシンを用いる治療を含んでなる、請求項１〜４のいずれか１項に記載の使用。
  17. 上記治療が(i)上記ヒストンデアセチラーゼ阻害剤と(ii)タモキシフェンを用いる治療を含んでなる、請求項１〜４のいずれか１項に記載の使用。
  18. 上記治療が(i)上記ヒストンデアセチラーゼ阻害剤と(ii)5-アザシチジンを用いる治療を含んでなる、請求項１〜４のいずれか１項に記載の使用。
  19. 上記治療が(i)上記ヒストンデアセチラーゼ阻害剤と(ii)クロランブシルを用いる治療を含んでなる、請求項１〜４のいずれか１項に記載の使用。
  20. 上記治療が(i)上記ヒストンデアセチラーゼ阻害剤と(ii)フルダラビンを用いる治療を含んでなる、請求項１〜４のいずれか１項に記載の使用。
  21. 上記治療が(i)上記ヒストンデアセチラーゼ阻害剤と(ii)Alimta(登録商標)を用いる治療を含んでなる、請求項１〜４のいずれか１項に記載の使用。
  22. 上記治療が(i)上記ヒストンデアセチラーゼ阻害剤と(ii)メルファランを用いる治療を含んでなる、請求項１〜４のいずれか１項に記載の使用。
  23. 上記治療が(i)上記ヒストンデアセチラーゼ阻害剤と(ii)カルボプラチン／パクリタキセルを用いる治療を含んでなる、請求項１〜４のいずれか１項に記載の使用。
  24. 癌が肺癌である、請求項１〜２３のいずれか１項に記載の使用。
  25. 癌が多発性骨髄腫である、請求項１〜２３のいずれか１項に記載の使用。
  26. 癌がリンパ腫である、請求項１〜２３のいずれか１項に記載の使用。
  27. 癌が上皮性卵巣癌である、請求項１〜２３のいずれか１項に記載の使用。
  28. キットまたはパーツのキットであって、
    (a)ヒストンデアセチラーゼ阻害剤；および
    (b)他の化学治療薬または上皮成長因子レセプター（EGFR）阻害剤を含み、かつ
    癌を治療する方法に使用するのに好適である、上記キットまたはパーツのキット。
JP2007553700A 2005-02-03 2006-02-03 Ｈｄａｃ阻害剤を用いる併用療法 Expired - Fee Related JP5156392B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US64999105P 2005-02-03 2005-02-03
US60/649,991 2005-02-03
US73566205P 2005-11-10 2005-11-10
US60/735,662 2005-11-10
PCT/GB2006/000391 WO2006082428A2 (en) 2005-02-03 2006-02-03 Combination therapies using hdac inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012031556A Division JP5640026B2 (ja) 2005-02-03 2012-02-16 Ｈｄａｃ阻害剤を用いる併用療法

Publications (3)

Publication Number Publication Date
JP2008528671A JP2008528671A (ja) 2008-07-31
JP2008528671A5 true JP2008528671A5 (ja) 2012-04-19
JP5156392B2 JP5156392B2 (ja) 2013-03-06

Family

ID=36178242

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2007553700A Expired - Fee Related JP5156392B2 (ja) 2005-02-03 2006-02-03 Ｈｄａｃ阻害剤を用いる併用療法
JP2012031556A Expired - Fee Related JP5640026B2 (ja) 2005-02-03 2012-02-16 Ｈｄａｃ阻害剤を用いる併用療法
JP2014026011A Pending JP2014111642A (ja) 2005-02-03 2014-02-14 Ｈｄａｃ阻害剤を用いる併用療法
JP2015081543A Pending JP2015147794A (ja) 2005-02-03 2015-04-13 Ｈｄａｃ阻害剤を用いる併用療法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2012031556A Expired - Fee Related JP5640026B2 (ja) 2005-02-03 2012-02-16 Ｈｄａｃ阻害剤を用いる併用療法
JP2014026011A Pending JP2014111642A (ja) 2005-02-03 2014-02-14 Ｈｄａｃ阻害剤を用いる併用療法
JP2015081543A Pending JP2015147794A (ja) 2005-02-03 2015-04-13 Ｈｄａｃ阻害剤を用いる併用療法

Country Status (7)

Country Link
US (3) US20080213399A1 (ja)
EP (7) EP2502649A1 (ja)
JP (4) JP5156392B2 (ja)
AU (1) AU2006210746B2 (ja)
CA (1) CA2596210C (ja)
NZ (2) NZ599464A (ja)
WO (1) WO2006082428A2 (ja)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8017321B2 (en) 2004-01-23 2011-09-13 The Regents Of The University Of Colorado, A Body Corporate Gefitinib sensitivity-related gene expression and products and methods related thereto
ES2537631T3 (es) 2004-05-27 2015-06-10 The Regents Of The University Of Colorado Métodos para la predicción del resultado clínico para inhibidores del receptor del factor de crecimiento epidérmico para pacientes de cáncer
EP2502649A1 (en) 2005-02-03 2012-09-26 TopoTarget UK Limited Combination therapy using HDAC inhibitors and erlotinib for treating cancer
AU2006223086A1 (en) * 2005-03-11 2006-09-21 The Regents Of The University Of Colorado Histone deacetylase inhibitors sensitize cancer cells to epidermal growth factor inhibitors
KR101329437B1 (ko) 2005-05-13 2013-11-14 토포타겟 유케이 리미티드 Ｈｄａｃ 억제제의 약학 제형
AU2006311820A1 (en) * 2005-11-04 2007-05-18 Merck Sharp & Dohme Corp. Methods of using SAHA and erlotinib for treating cancer
JP5377968B2 (ja) * 2005-11-10 2013-12-25 トポターゲット ユーケー リミテッド 癌治療のために単独で用いるまたは化学療法薬と併用するヒストンデアセチラーゼ（ｈｄａｃ）阻害剤
US7547781B2 (en) 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
CN101641338A (zh) * 2006-09-11 2010-02-03 柯瑞斯公司 作为抗增殖制剂的多功能小分子
AU2007296743B2 (en) 2006-09-11 2012-02-16 Curis, Inc. Tyrosine kinase inhibitors containing a zinc binding moiety
US7977347B2 (en) 2006-09-11 2011-07-12 Curis, Inc. Quinazoline based EGFR inhibitors
JP2010502743A (ja) * 2006-09-11 2010-01-28 キュリス，インコーポレイテッド 抗増殖薬剤としての多機能性低分子
SG174774A1 (en) 2006-09-11 2011-10-28 Curis Inc Quinazoline based egfr inhibitors containing a zinc binding moiety
AU2007296740B2 (en) 2006-09-11 2012-09-27 Curis, Inc. Substituted 2-indolinone as PTK inhibitors containing a zinc binding moiety
US8110550B2 (en) 2007-06-06 2012-02-07 University Of Maryland, Baltimore HDAC inhibitors and hormone targeted drugs for the treatment of cancer
TW200922564A (en) 2007-09-10 2009-06-01 Curis Inc CDK inhibitors containing a zinc binding moiety
WO2009035718A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Tartrate salts or complexes of quinazoline based egfr inhibitors containing a zinc binding moiety
US8119616B2 (en) 2007-09-10 2012-02-21 Curis, Inc. Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety
CN101868446A (zh) 2007-09-25 2010-10-20 托波塔吉特英国有限公司 某些异羟肟酸化合物的合成方法
US20110053991A1 (en) * 2007-11-19 2011-03-03 Gore Lia Treatment of Histone Deacetylase Mediated Disorders
MX2010009642A (es) * 2008-03-07 2010-09-22 Topotarget As Metodos de tratamiento utilizando infusion continua prolongada de belinostat.
TWI558710B (zh) 2009-01-08 2016-11-21 古利斯股份有限公司 具有鋅連接部位的磷酸肌醇３－激酶抑制劑
GB0900555D0 (en) * 2009-01-14 2009-02-11 Topotarget As New methods
ES2621849T3 (es) * 2009-06-26 2017-07-05 Sunny Pharmtech Inc. Método de tratamiento o mejora de toxicidades mucocutáneas u oculares.
WO2011127482A2 (en) * 2010-04-09 2011-10-13 The Salk Institute For Biological Studies Modulation of histone deacetylases for the treatment of metabolic disease, methods and compositions related thereto
RU2016103126A (ru) * 2010-06-07 2018-11-22 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Способы комбинированной терапии для лечения пролиферативных заболеваний
HUE028910T2 (en) 2011-04-01 2017-01-30 Curis Inc Phosphonoinoside-3-kinase inhibitor with zinc-binding radical
GB201217439D0 (en) * 2012-09-28 2012-11-14 Topotarget As Combination therapy
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
US11998546B2 (en) * 2016-10-28 2024-06-04 Acetylon Pharmaceuticals, Inc. Pharmaceutical combinations comprising a histone deacetylase inhibitor and epothilone and methods of use thereof
CN110769852A (zh) 2017-04-05 2020-02-07 国立大学法人千叶大学 Swi/snf复合物的功能抑制剂
US20190046513A1 (en) * 2017-08-10 2019-02-14 Huya Bioscience International, Llc Combination therapies of hdac inhibitors and tubulin inhibitors
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
EP3849554A4 (en) 2018-09-11 2022-06-01 Curis, Inc. POLYTHERAPY WITH A PHOSPHOINONOSITIDE 3-KINASE INHIBITOR HAVING A ZINC-BINDING METAL
EP4366716A4 (en) * 2021-07-08 2024-10-23 Klotho Therapeutics Inc NEW METHODS OF COMBINATORIAL ANTITUMOR TREATMENT AND RELATED COMPOSITIONS, KITS AND SYSTEMS
WO2024091201A1 (en) * 2022-10-26 2024-05-02 Bilecik Seyh Edebali Universitesi A combined drug for the treatment of triple negative breast cancer

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4642316A (en) 1985-05-20 1987-02-10 Warner-Lambert Company Parenteral phenytoin preparations
US6071923A (en) * 1994-09-16 2000-06-06 Bar-Ilan University Retinoyloxy aryl-substituted alkylene butyrates useful for the treatment of cancer and other proliferative diseases
US5730977A (en) 1995-08-21 1998-03-24 Mitsui Toatsu Chemicals, Inc. Anti-VEGF human monoclonal antibody
DK0923941T3 (da) * 1996-06-27 2006-09-18 Chugai Pharmaceutical Co Ltd Midler mod myelom der skal anvendes sammen med nitrogensennepantitumormidler
EP0827742A1 (en) 1996-09-04 1998-03-11 Vrije Universiteit Brussel Use of histone deacetylase inhibitors for treating fribosis or cirrhosis
TR200101049T2 (tr) * 1998-10-13 2002-01-21 Fujisawa Pharmaceutical Co. Ltd. Siklik tetrapeptid bileşiği ve kullanımı
US20070148228A1 (en) 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
US6316435B2 (en) * 1999-02-24 2001-11-13 Supergen, Inc. Combination therapy for lymphoproliferative diseases
CA2372053C (en) * 1999-04-28 2008-09-02 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
US7105560B1 (en) * 1999-07-23 2006-09-12 The Regents Of The University Of California Use of etodolac in the treatment of multiple myeloma
US6541661B1 (en) 1999-11-23 2003-04-01 Methylgene, Inc. Inhibitors of histone deacetylase
GB0023983D0 (en) 2000-09-29 2000-11-15 Prolifix Ltd Therapeutic compounds
JP4975941B2 (ja) 2000-09-29 2012-07-11 トポターゲット ユーケー リミテッド （ｅ）−ｎ−ヒドロキシ−３−（３−スルファモイル−フェニル）アクリルアミド化合物及びその治療用途
DK1335898T3 (da) * 2000-09-29 2006-04-03 Topotarget Uk Ltd Carbaminsyreforbindelser omfattende en amidbinding som HDAC-inhibitorer
WO2002074298A1 (fr) 2001-03-21 2002-09-26 Ono Pharmaceutical Co., Ltd. Inhibiteurs de production d'il-6
EP1390491B1 (en) 2001-05-02 2008-07-16 The Regents of the University of California Method for treating neurodegenerative, psychiatric and other disorders with deacetylase inhibitors
AU2002318364A1 (en) * 2001-06-14 2003-01-02 Bristol-Myers Squibb Company Novel human histone deacetylases
JP4529119B2 (ja) 2001-08-09 2010-08-25 小野薬品工業株式会社 カルボン酸誘導体化合物およびその化合物を有効成分として含有する薬剤
JP4238728B2 (ja) 2001-08-21 2009-03-18 アステラス製薬株式会社 ヒストンデアセチラーゼ阻害剤の医薬用途ならびにその抗腫瘍効果の評価方法
US6897220B2 (en) 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
EP1293205A1 (en) * 2001-09-18 2003-03-19 G2M Cancer Drugs AG Valproic acid and derivatives thereof for the combination therapy of human cancers, for the treatment of tumour metastasis and minimal residual disease
AU2002337713A1 (en) * 2001-09-26 2003-04-07 Intermune, Inc. Pharmaceutical compositions and methods for treating cancer
EP1461457A4 (en) * 2001-11-28 2005-08-10 Dnaprint Genomics Inc INDIVIDUAL NUCLEOTIDE POLYMORPHISMS AND THEIR COMBINATIONS TO PREDICT THE APPEAL ON PACLITAXEL
RU2301666C2 (ru) 2002-01-11 2007-06-27 Маттиас Рат Обладающий питательными свойствами фармацевтический состав на основе полифенолов и его использование при лечении рака
US20060058553A1 (en) 2002-02-07 2006-03-16 Axys Pharmaceuticals, Inc. Novel bicyclic hydroxamates as inhibitors of histone deacetylase
WO2003070188A2 (en) 2002-02-15 2003-08-28 Sloan-Kettering Institute For Cancer Research Method of treating trx mediated diseases
US20050288227A1 (en) 2002-02-15 2005-12-29 Marks Paul A Use of thioredoxin measurements for diagnostics and treatments
US7148257B2 (en) 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
US20040132825A1 (en) 2002-03-04 2004-07-08 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
ES2532607T3 (es) * 2002-03-04 2015-03-30 Merck Hdac Research, Llc Métodos de inducción de la diferenciación terminal
US20070060614A1 (en) 2002-03-04 2007-03-15 Bacopoulos Nicholas G Methods of treating cancer with hdac inhibitors
EA007272B1 (ru) * 2002-03-13 2006-08-25 Янссен Фармацевтика Н. В. Новые ингибиторы гистондеацетилазы
AU2002243097A1 (en) 2002-04-03 2003-10-13 Hyundai Pharm. Ind. Co., Ltd. Quinoline derivatives, their preparation and pharmaceutical compositions comprising the same
TWI319387B (en) 2002-04-05 2010-01-11 Astrazeneca Ab Benzamide derivatives
WO2003087066A1 (en) 2002-04-11 2003-10-23 Sk Chemicals, Co., Ltd. α,β-UNSATURATED HYDROXAMIC ACID DERIVATIVES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS
CN100566711C (zh) * 2002-04-15 2009-12-09 斯隆-凯特林癌症研究院 治疗癌症的化合物及其用途
US8883148B2 (en) 2002-04-26 2014-11-11 Asan Laboratories Company (Cayman), Limited Prevention of joint destruction
GB0209715D0 (en) 2002-04-27 2002-06-05 Astrazeneca Ab Chemical compounds
AU2003253681B2 (en) * 2002-06-24 2008-05-01 Research Development Foundation Treatment of human multiple myeloma by Curcumin
DE10233412A1 (de) 2002-07-23 2004-02-12 4Sc Ag Neue Verbindungen als Histondeacetylase-Inhibitoren
BR0313371A (pt) 2002-08-02 2005-07-05 Argenta Discovery Ltd Composto, uso de um composto e método de tratamento de doença
US20080004311A1 (en) 2002-11-12 2008-01-03 Alcon, Inc. Histone deacetylase inhibitors for treating degenerative diseases of the eye
GB0226370D0 (en) * 2002-11-12 2002-12-18 Novartis Ag Organic compounds
ITMI20030025A1 (it) 2003-01-10 2004-07-11 Italfarmaco Spa Derivati dell'acido idrossammico ad attivita' antinfiammatoria.
TW200418806A (en) 2003-01-13 2004-10-01 Fujisawa Pharmaceutical Co HDAC inhibitor
WO2004064727A2 (en) * 2003-01-16 2004-08-05 Georgetown University Method of cancer treatment using hdac inhibitors
TW200424174A (en) 2003-02-06 2004-11-16 Hoffmann La Roche New TP diamide
AU2003900608A0 (en) 2003-02-11 2003-02-27 Fujisawa Pharmaceutical Co., Ltd. Hdac inhibitor
US7244751B2 (en) 2003-02-14 2007-07-17 Shenzhen Chipscreen Biosciences Ltd. Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity
EP1597390A4 (en) * 2003-02-18 2006-12-27 Maxcyte Inc LOADING CELLS WITH ANTIGENES BY ELECTROPORATION
KR20050122210A (ko) 2003-03-17 2005-12-28 다케다 샌디에고, 인코포레이티드 히스톤 탈아세틸화 효소 억제제
TW200424187A (en) 2003-04-04 2004-11-16 Hoffmann La Roche New oxime derivatives and their use as pharmaceutically active agents
AU2004230889B2 (en) 2003-04-07 2008-03-13 Pharmacyclics Llc Hydroxamates as therapeutic agents
US20040220242A1 (en) 2003-05-02 2004-11-04 Leland Shapiro Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide induced clinical conditions
AU2004252067B2 (en) 2003-05-09 2012-04-12 Duke University CD20-specific antibodies and methods of employing same
JP2006528952A (ja) * 2003-05-21 2006-12-28 ノバルティス アクチエンゲゼルシャフト ヒストンデアセチラーゼ阻害剤と化学療法剤の組み合わせ
EP1491188A1 (en) 2003-06-25 2004-12-29 G2M Cancer Drugs AG Topical use of valproic acid for the prevention or treatment of skin disorders
DE602004026321D1 (de) 2003-08-26 2010-05-12 Merck Hdac Res Llc Verwendung von SAHA zur Behandlung von Mesotheliom
EP1667680A4 (en) * 2003-08-29 2008-10-08 Aton Pharma Inc COMBINED METHODS OF TREATING CANCER
WO2005052143A2 (de) 2003-11-14 2005-06-09 Per Sonne Holm Neue adenoviren, dafür codierende nukleinsäuren und deren verwendung
US20070110719A1 (en) 2003-11-14 2007-05-17 Holm Per S Novel use of adenoviruses and nucleic acids that code for said viruses
WO2005063806A1 (en) 2003-12-30 2005-07-14 Council Of Scientific And Industrial Research Arginine hydrochloride enhances chaperone-like activity of alpha crystallin
GB0401876D0 (en) 2004-01-28 2004-03-03 Vereniging Het Nl Kanker I New use for cancer antigen
WO2005085864A1 (en) 2004-02-27 2005-09-15 The Government Of The United States Of America, Asrepresented By The Secretary Of The Department Of Health And Human Services Pharmacodynamic assays using flow cytometry
PL1591109T3 (pl) 2004-04-30 2008-11-28 Topotarget Germany Ag Preparat zawierający inhibitor deacetylazy histonów wykazujący dwufazowe uwalnianie”
EP2476427B1 (en) 2004-08-02 2018-01-17 Zenyth Operations PTY. Ltd. A method of treating cancer comprising a VEGF-B antagonist
JPWO2006014024A1 (ja) 2004-08-06 2008-05-01 小野薬品工業株式会社 精神神経系疾患治療剤
JP4946861B2 (ja) 2004-08-09 2012-06-06 アステラス製薬株式会社 ヒストンデアセチラーゼ（ｈｄａｃ）の阻害活性を有するヒドロキシアミド化合物
US8889742B2 (en) 2004-11-30 2014-11-18 The Trustees Of The University Of Pennsylvania Use of HDAC and/or DNMT inhibitors for treatment of ischemic injury
FR2879204B1 (fr) 2004-12-15 2007-02-16 Lab Francais Du Fractionnement Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b.
CA2610360A1 (en) 2004-12-31 2006-07-06 Per Sonne Holm E1-minus adenoviruses and use thereof
JP5475235B2 (ja) 2005-01-21 2014-04-16 アステックス・セラピューティクス・リミテッド 医薬化合物
EP2502649A1 (en) 2005-02-03 2012-09-26 TopoTarget UK Limited Combination therapy using HDAC inhibitors and erlotinib for treating cancer
US20060229237A1 (en) 2005-04-07 2006-10-12 Yih-Lin Chung Treatment of gastrointestinal distress
GB0509225D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Inhibitors of enzymatic activity
KR101329437B1 (ko) 2005-05-13 2013-11-14 토포타겟 유케이 리미티드 Ｈｄａｃ 억제제의 약학 제형
EP1743654A1 (en) 2005-07-15 2007-01-17 TopoTarget Germany AG Use of inhibitors of histone deacetylases in combination with NSAID for the therapy of cancer and/or inflammatory diseases
EP1924245A2 (en) 2005-08-19 2008-05-28 Government of the United States of America, Represented by the Secretary, Department of Health and Human Services Topical formulations of histone deacetylase inhibitors and methods of using the same
AU2006287521A1 (en) 2005-09-07 2007-03-15 Plexxikon, Inc. PPARactive compounds
WO2007049262A1 (en) 2005-10-27 2007-05-03 Berand Limited Methods and compositions for the promotion of neuronal growth and the treatment of asociality and affective disorders
JP5377968B2 (ja) 2005-11-10 2013-12-25 トポターゲット ユーケー リミテッド 癌治療のために単独で用いるまたは化学療法薬と併用するヒストンデアセチラーゼ（ｈｄａｃ）阻害剤
US8445198B2 (en) 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
US8530493B2 (en) 2006-02-22 2013-09-10 4Sc Ag Indolopyridines as Eg5 kinesin modulators
AU2007217562A1 (en) 2006-02-22 2007-08-30 4Sc Ag Indolopyridines as EG5 kinesin modulators
GB0606096D0 (en) 2006-03-27 2006-05-03 Cbmm Sa Screening method
EP1839656A1 (en) 2006-03-31 2007-10-03 TopoTarget Germany AG Use of valproic acid for the topical treatment of mild to moderate acne vulgaris
EP2026805A1 (en) 2006-05-08 2009-02-25 Astex Therapeutics Limited Pharmaceutical combinations of diazole derivatives for cancer treatment
CA2654566A1 (en) 2006-06-09 2007-12-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
WO2008011603A2 (en) 2006-07-20 2008-01-24 Wisconsin Alumni Research Foundation Modulating notch1 signaling pathway for treating neuroendocrine tumors
US20080242648A1 (en) 2006-11-10 2008-10-02 Syndax Pharmaceuticals, Inc., A California Corporation COMBINATION OF ERa+ LIGANDS AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER
US8796330B2 (en) 2006-12-19 2014-08-05 Methylgene Inc. Inhibitors of histone deacetylase and prodrugs thereof
WO2008090534A1 (en) 2007-01-26 2008-07-31 Berand Limited Methods and compositions for inhibition of excessive weight gain, reduction of inappropriate eating behaviours and inhibition of binge eating for the treatment of obesity
US7915245B2 (en) 2007-02-01 2011-03-29 The Board Of Regents Of The University Of Texas System Methods and compositions of trail-death receptor agonists/activators
WO2008101121A2 (en) 2007-02-14 2008-08-21 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to promoter regulation by muc1 and klf proteins
WO2008136838A1 (en) 2007-05-04 2008-11-13 Trustees Of Dartmouth College Novel amide derivatives of cddo and methods of use thereof
US8110550B2 (en) 2007-06-06 2012-02-07 University Of Maryland, Baltimore HDAC inhibitors and hormone targeted drugs for the treatment of cancer
US20090246198A1 (en) 2008-03-31 2009-10-01 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
US20090270497A1 (en) 2008-04-24 2009-10-29 Pharmacyclics, Inc. Treatment of Non-Localized Inflammation with pan-HDAC Inhibitors
US8637554B2 (en) 2008-05-07 2014-01-28 The Trustees Of The University Of Pennsylvania Methods for treating thyroid cancer

Similar Documents

Publication Publication Date Title
JP2008528671A5 (ja)
RU2605335C2 (ru) Комбинированная терапия противоопухолевым алкалоидом
JP2010504079A5 (ja)
WO2016210106A1 (en) Compositions and methods for inhibiting arginase activity
RU2020114632A (ru) Терапевтические способы, относящиеся к ингибиторам hsp90
JP2008508287A5 (ja)
JP2010533206A5 (ja)
JP2009536191A5 (ja)
WO2016160980A1 (en) Methods of administering glutaminase inhibitors
JP2020523354A5 (ja)
JP2017526662A5 (ja)
JP2008525493A5 (ja)
ES2625492T3 (es) Combinación terapéutica que comprende un inhibidor de Cdc7 y un agente antineoplásico
JP2008528617A5 (ja)
JP2014512355A5 (ja)
JP2019513812A5 (ja)
JP2004532883A5 (ja)
JP2018516936A5 (ja)
JPWO2020163823A5 (ja)
TW200530154A (en) Compounds having antitumor activity
JP2013523867A5 (ja)
JP5694782B2 (ja) 肺癌、腺癌及び他の病状のための治療方法及び組成物
JP2009534449A5 (ja)
JP2010500971A5 (ja)
RU2012140020A (ru) Гетероциклические соединения и их применение в качестве противораковых средств